Cookie Img Back to top
Send SMS    Call Me Free Offline
Home » Products » Sofosbuvir » Zydus Launch SoviHep

Zydus Launch SoviHep

Zydus Launch SoviHep
Zydus Launch SoviHep
Send Inquiry
Product Code : 156
Brand Name : Sovihep
Product Description

Having both quality and clients centric approach, we have been occupied in exporting and supplying a premium range of Zydus Launch SoviHep. This product is formulated using quality approved chemical compounds by ingenious professionals as per set medical standards. Offered product is widely prescribed by doctors for treating of hepatitis C virus, that spreads due to blood contact and further leads to failure of lung. Additionally, our precious clients can buy this Zydus Launch SoviHep from us at most remarkable costs.

Key Points:

  • Highly effective
  • Free from harmful impurities
  • Longer shelf life
  • Fewer side effects

Zydus and Gilead Sciences Inc has signed a non-exclusive licensing agreement which  will allow the manufacture of sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for distribution in 91 countries including India. The company said that the oral therapy would be able to help  more than 10 million patients who suffer from Hepatitis C in India.

Hepatitis C is an infectious disease affecting primarily the liver, caused by the Hepatitis C Virus (HCV). It spreads primarily through blood-to-blood contact associated with poorly sterilised medical equipment, and transfusions. An estimated 150 200 million people worldwide are infected with hepatitis C. The infection is often asymptomatic, but chronic infection can lead to scarring of the liver and cirrhosis. Some patients may also develop liver failure, liver cancer, or life-threatening complications. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.

For over a decade in India, the disease has been treated with PEG-IFN along with Ribavirin. However, the management of the disease has been a challenge with less than one per cent of 10 million Hepatitis C patients having access to treatment. The problem is further compounded by the fact that patients remain undiagnosed till the late stage and can ill afford the treatment.